Lu J, Wu L, Sun Y, Huang X, Gao C, Guo X, et al. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. Nat Commun. 2024;15:621 pubmed publisher

Pedersen J, Hansen A, Skej xf8 C, Juul Madsen K, Junker P, H xf8 rslev Petersen K, et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Res Ther. 2023;25:97 pubmed publisher

Wu L, Brzostek J, Sakthi Vale P, Wei Q, Koh C, Ong J, et al. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Rep Med. 2023;4:100917 pubmed publisher

Asashima H, Mohanty S, Comi M, Ruff W, Hoehn K, Wong P, et al. PD-1highCXCR5-CD4+ peripheral helper T cells promote CXCR3+ plasmablasts in human acute viral infection. Cell Rep. 2023;42:111895 pubmed publisher

Wang H, Cao K, Liu S, Xu Y, Tang L. Tim-3 Expression Causes NK Cell Dysfunction in Type 2 Diabetes Patients. Front Immunol. 2022;13:852436 pubmed publisher

Vorkas C, Krishna C, Li K, AUBE J, Fitzgerald D, Mazutis L, et al. Single-Cell Transcriptional Profiling Reveals Signatures of Helper, Effector, and Regulatory MAIT Cells during Homeostasis and Activation. J Immunol. 2022;208:1042-1056 pubmed publisher

Warmuth S, Gunde T, Snell D, Brock M, Weinert C, Simonin A, et al. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. Oncoimmunology. 2021;10:2004661 pubmed publisher

Deng W, Su Z, Liang P, Ma Y, Liu Y, Zhang K, et al. Single-cell immune checkpoint landscape of PBMCs stimulated with Candida albicans. Emerg Microbes Infect. 2021;10:1272-1283 pubmed publisher

Paul S, Pearlman A, Douglass J, Mog B, Hsiue E, Hwang M, et al. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers. Sci Transl Med. 2021;13: pubmed publisher

Si J, Shi X, Sun S, Zou B, Li Y, An D, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020;38:551-566.e11 pubmed publisher

Juillerat A, Tkach D, Yang M, Boyne A, Valton J, Poirot L, et al. Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells. Front Bioeng Biotechnol. 2020;8:678 pubmed publisher

Zah E, Nam E, Bhuvan V, Tran U, Ji B, Gosliner S, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11:2283 pubmed publisher

Suzuki S, Ogawa T, Sano R, Takahara T, Inukai D, Akira S, et al. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Sci. 2020;111:1943-1957 pubmed publisher

Darcis G, Kootstra N, Hooibrink B, van Montfort T, Maurer I, Groen K, et al. CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency. Cell Rep. 2020;30:2284-2296.e3 pubmed publisher